PR Newswire Asia's news > Medical/Pharmaceuticals

 |   Title only   |   Print    Next page > 
     
Bridging Geographical Boundaries: Abrobo's Groundbreaking Contribution to China Medical Innovation-- the World's First Live Broadcast of Remote Cerebrovascular Interventional Operation on Animal at an Academic Conference
SHANGHAI , Oct. 31, 2024 /PRNewswire/ -- This golden October, great minds gathered to embark on a new chapter of innovation. The 2024 Oriental Conference of Interventional Neurovascology (OCIN 2024), ...
2024-10-31T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
TAIPEI , Oct. 31, 2024 /PRNewswire/ -- Taiwan -based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with ...
2024-10-31T    Health Care/Hospital   Medical/Pharmaceuticals 
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024
WASHINGTON , Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company" ) (HKEX: 9877), an innovative medical device company dedicated to interventional ...
2024-10-31T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services
HONG KONG and SHANGHAI , Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited  (" Ping An Good Doctor ", "Ping An Health", or "the Company", ...
2024-10-31T    Health Care/Hospital   Medical/Pharmaceuticals 
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases ...
2024-10-31T    Health Care/Hospital   Medical/Pharmaceuticals 
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...
2024-10-31T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
BOSTON , Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the ...
2024-10-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)
Celltrion USA has expanded access to  ZYMFENTRA ®   (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab,  to a significant share of the ...
2024-10-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK
This approval marks the second international marketing authorization for sugemalimab outside of China , following its recent approval by the European Commission. The approval is based on results ...
2024-10-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China , Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the " Application ") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of ...
2024-10-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

 

88iv | Home |  Login
Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer
Copyright (C) 2024
Suntek Computer Systems Limited.
All rights reserved